Moderna to seek COVID vaccine's limited emergency use


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ moderna-seek-covid-vaccines-limited-emergency-use
Moderna's vaccine candidate - mRNA-1273 - is nearing the finish line in its push to enroll 30,000 individuals in a late-stage trial of a novel coronavirus vaccine.

If Moderna Inc's COVID-19 vaccine proves to be at least 70% effective, the company plans to seek emergency authorization for its use in high-risk groups, the company's chief executive told Reuters.

Moderna's vaccine candidate - mRNA-1273 - is nearing the finish line in its push to enroll 30,000 individuals in a late-stage trial of a novel coronavirus vaccine. As of Wednesday night, Moderna had enrolled 25,296 participants.

But the company may be able to declare victory early if it can show that people who got the vaccine fared much better in its trial that people who did not.

Vaccines must demonstrate they are at least 50% more effective than a placebo to be considered for approval. To prove that, government officials have said, at least 150 COVID-19infections must be recorded among trial participants with at least twice as many occurring among the placebo group. If a vaccine is especially effective, companies could have their answer sooner.

An independent safety board will take a first look at Moderna's data as soon as a total of 53 people in the trial become infected with COVID-19. Moderna is projecting the interim analysis will occur in November, but it could come as early as October.

If most of the people who got sick got the placebo shot, that would indicate the vaccine was protecting those inoculated and could be enough evidence to seek U.S. regulatory approval for Emergency Use Authorization (EUA).

"If the interim readout is deemed by the independent safety committee as positive with 70 or 80 or 90% efficacy, we will indeed consider approval," Stephane Bancel, Moderna's chief executive officer, said in a telephone interview.

"At such a level of efficacy, if we get there, we can protect a lot of lives in the people at the highest risk, and so, we will consider filing for a EUA for a very limited population," Bancel said.

He said the Food and Drug Administration will determine whether the benefit of the vaccine to a small group of high-risk individuals outweighs the risk of not having a full readout of safety data from all 30,000 study participants.

The two groups of high-risk individuals who might be covered in such a EUA would be healthcare workers and the elderly, Bancel said.

In a conference call with investors on Thursday, Bancel said he expects the company to file for a EUA in 2020, and full FDA approval.

He told Reuters the company wants to gather more data on the safety of the vaccine in the study population over several months before seeking full licensure.

Moderna released its study protocol on Thursday, making public details on how its vaccine will be evaluated. If the vaccine does not reach the efficacy mark after 53 cases, the data safety and monitoring board will take another interim look at the data after 106 cases, and a final look after 151 people in the trial become infected with the virus.

Public health officials have said that approving a vaccine for widespread use based on a small number of cases would not offer enough safety information to show how the vaccine would perform.

Moderna, which has never brought a vaccine to market, has received nearly $1 billion from the U.S. government under its operation Warp Speed program. It has also struck a $1.5 billion supply agreement with the United States.

On the call, the company said it is on track to deliver 500 million to 1 billion doses of the vaccine annually. In the United States, decisions about vaccine allocation will be made by the U.S. government, the company said.

Moderna also announced plans to start developing seasonal flu vaccines.

In a presentation to investors on Tuesday, Pfizer Inc said the company has enrolled more than 29,000 people in its 44,000-volunteer trial to test an experimental COVID-19 vaccine the company is developing with German partner BioNTech.

Pfizer expects to have enough data to show whether the vaccine works by the end of October.

Tags : #Moderna #Vaccine #COVID-19 #Emergency

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

ACT Fibernet Collaborates with Amazon Prime to Offer Prime Lite Benefits to Consumers June 19, 2025
CARE Hospitals Conducts “The Power of 3” Public Awareness Drive at Punjagutta JunctionJune 19, 2025
Legalising key population led health services in Thailand is a gamechangerJune 19, 2025
MGM Healthcare Successfully Performs Rare Endoscopic Skull Base Surgery on a 1-Year-Old with Brain Herniation inside NoseJune 19, 2025
Asian Paints’ Apcolite All Protek redefines the Gold Standard in Interior Paints with Breakthrough ‘Lotus Effect Technology’June 19, 2025
The Soft Touch of Tomorrow: Rural India's Lives Are Being Changed by 3D-Printed LimbsJune 19, 2025
QNET India Celebrates International Yoga Day with Curated Wellness EssentialsJune 18, 2025
illumine Raises $2.5M Seed Funding to Globally Scale Vertical AI Platform for Childcare ManagementJune 18, 2025
Mykare Achieves EBITDA-Positive Status in Elective Surgery Vertical with 80% Revenue GrowthJune 18, 2025
HCG Manavata Cancer Centre Launches Scalp Cooling Therapy To Prevent Chemotherapy-Induced Hair LossJune 18, 2025
Biohacking in India: From Blue Light Glasses to Metabolic TrackingJune 18, 2025
AI-Generated Prescriptions: Will They Ever Be Safe Enough?June 18, 2025
The Role of Panchayats in Public Health: Untapped Potential in Rural GovernanceJune 18, 2025
When Medicines Stop Working: How Communities in India Are Fighting BackJune 18, 2025
Archish Fertility & IVF, India’s First 100% Fully Transparent Fertility Lab, Partners with Amaha Health for Holistic Patient Support & Mental WellbeingJune 17, 2025
Supporting Mental Health in AutismJune 17, 2025
New guidelines for monitoring IBD patients to prevent bowel cancerJune 17, 2025
TTK Prestige Launches Tri-Ply Hexamagic Cookware, Blending Non-Stick Innovation with Triply DurabilityJune 17, 2025
Turning ₹2.35 Crore of Grant into ₹17.9 Crore of Impact: How Villgro-360 ONE’s Capital For Impact is Benefitting Thousands of Marginalised FarmersJune 17, 2025
Online Chikitsa Mitra Rolls Out Mobile App for Specialized, In-Home HealthcareJune 17, 2025